Insulet : 2025 Sustainability Report
PODD
Published on 05/04/2026 at 12:25 pm EDT
2025
SUSTAINABILITY REPORT
Table of Contents
Introduction
3
Sustainability Approach
23
Sustainable Product Innovation
38
Governance
69
Message From Our CEO
4
Message From Our CSO
24
Circular Economy and Product Stewardship
39
Key Governance Practices
70
About Insulet
5
2025 Sustainability Performance
25
Product Quality and Safety
44
Ethics, Compliance, and Anti-Corruption
71
Awards
7
Materiality
26
Cybersecurity and Data Privacy
74
Extending Our Leadership and Growth
8
Our Stakeholders
27
People and Communities
47
Responsible Marketing
76
Sustainability Strategy
28
Value, Affordability, Advocacy, and Access
48
Our Products 9
Omnipod® 5 11
Customer Centricity 17
Resilient Operations 29
Social Impact
54
Appendix
77
Employee Experience
59
About This Report
78
Workplace Health and Safety
67
Scope 1 & 2 Emissions Basis of Reporting
80
Data Tables
82
SASB Index
84
GRI Content Index
87
TCFD Index
95
Energy and GHG Emissions 30
Supplier Responsibility 34
Human Rights 37
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 3
Introduction
When we broaden access to our products, use resources responsibly, and design with sustainability in mind, our customers, communities, and planet benefit
IN THIS SECTION
Message From Our CEO 4
About Insulet 5
Awards 7
Extending Our Leadership and Growth 8
INSULET | SUSTAINABILITY REPORT 2025
"
Our growth is grounded in a clear focus that reflects our sustainability vision: to deliver growth with purpose, innovating to improve lives and preserve our planet.
Message From Our CEO
Every day, people with diabetes make a variety of big and small decisions to manage their health. At Insulet, we focus on reducing that burden, improving clinical outcomes for people with diabetes and unlocking greater freedom, independence, and joy.
For 25 years, this focus has driven how we innovate, grow, and operate. It reflects our vision and mission as a Company and the simple belief that always shapes our priorities: there has to be a better way.
Today, more than 600,000 Podders around the world rely on Omnipod to manage their diabetes with greater flexibility and confidence. Each new customer start represents a person whose daily burden just became lighter - and a reminder of the global opportunity that exists for us to reach millions more people who can benefit from our technology.
In 2025, we delivered strong and responsible growth while expanding our impact. We extended
Omnipod 5 into nine new markets, strengthened integration with leading continuous glucose monitoring systems, and advanced our innovation pipeline to further simplify care. We also accelerated momentum in type 2 diabetes, supported by strong clinical
evidence and a growing recognition of automated insulin delivery (AID) as the standard of care.
Our growth is grounded in a clear focus that reflects our sustainability vision: to deliver growth with purpose, innovating to improve lives and preserve our planet. As we continue to drive growth, we work to reach more people, strengthen our systems, and deliver enduring value for all our stakeholders.
Expanding access remains central to our efforts. Through our HealthTech for All initiatives, we are deepening partnerships in underserved communities, expanding financial assistance programs, and supporting the diabetes community as they navigate the healthcare system. We are also working to broaden education and awareness by bringing AID beyond endocrinology and into primary care to help more people benefit from our technology.
At the same time, we are building a more resilient and efficient business to support our growth ambition and initiatives. We invest in advanced manufacturing and supply chain capabilities that enable us to scale production while continuously improving quality, reliability, and efficiency, ensuring we can meet growing global demands in a responsible and sustainable way.
Additionally, we remain focused on reducing our environmental impact and advancing more circular approaches to our products and packaging. From redesigning packaging to decreasing material use to expanding our Pod takeback programs - now available to more than 90% of our customers globally - we work to keep used Pods out of landfills and rethink how diabetes technology is designed, delivered, and recovered.
Our united, dedicated, and talented Insulet colleagues - 'Team Podd' - are essential to accomplishing our goals and objectives. As our workforce and global footprint continue to evolve, we remain committed to fostering a culture where employees feel supported, connected, and empowered. Through our employee resource groups, volunteer initiatives, and giving programs, Team Podd is committed to contributing to the communities where we live and work.
As we move through this year and beyond, advancing innovation through the development of
next-generation platforms that improve outcomes, expand choice, and offer more personalized and automated solutions is our north star. We strive
to reach more people - across both type 1 and type 2 diabetes - by expanding access, strengthening partnerships, and advancing
standards of care globally. And, importantly, we continue to ensure the way we design, build, and deliver our technology reduces environmental impact and supports a more sustainable future.
We are proud of the progress we've made and are equally inspired by the opportunities that lie ahead to transform the lives of people with diabetes - every day and everywhere.
Thank you for believing in Team Podd and for being a part of our mission in motion!
Sincerely,
PRESIDENT AND CHIEF EXECUTIVE OFFICER
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
4
About Insulet
OUR VISION
A world where diabetes demands less, every day
and everywhere.
2025 BUSINES S HIGHLIGHT S
Achieved annual revenue
of $2.7B in 2025
Grew full-time employee base to over 5,400 globally, representing a 38% increase over 2024
Insulet products are available
in 25 countries
Omnipod 5 recognized as the No. 1 insulin pump for new pump users in both the U.S. and Europe in 20252
Over 1,000 patents and more than 700 patent applications pending
Omnipod 5 is the first and only AID system FDA-cleared for both type 1 and type 2 diabetes, with the type 2 indication for ages 18+1
600,000+ estimated global customers using Omnipod products3
Omnipod 5 available in more than 47,000 U.S. pharmacies
Insulet began with a simple but bold vision: a world where diabetes demands less, every day and everywhere. That belief has shaped everything the Company does.
OUR MIS SION
Born of empathy, driven by ingenuity, proven by science, we transform the lives of
people with diabetes.
Today, Insulet (Nasdaq: PODD) stands at the forefront of medical technology with its Omnipod product platform - a wearable, tubeless device designed to make insulin delivery simple. Instead of injections or tangled tubing, each small, disposable Pod delivers up to three days of continuous insulin without requiring users to ever see or handle a needle.
The Company's flagship system, Omnipod 5, connects with a continuous glucose monitor, automatically adjusts insulin delivery to help keep blood sugar in range - no multiple daily injections - no fingersticks - and can be controlled by a smartphone in the U.S. or by the Omnipod 5 Controller.
At its core, Insulet is driven by our mission: Born of empathy, driven by ingenuity, and proven by science, we transform the lives of people with diabetes.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
5
Utrecht, NL
Irvine, CA San Diego, CA
Tijuana Guadalajara
Mississauga, Ontario
Acton, MA
(Headquarters)
Nashville, TN
London
Paris
Waalwijk, NL Munich
Dubai
Kunshan, Jiangsu Shenzhen, Guangdong
LOCATIONS
Insulet is headquartered in Acton, Massachusetts, with additional offices in other parts of the U.S. and in Australia, Canada, China, England, France, Germany, Malaysia, Mexico, the Netherlands, and the UAE. We have manufacturing facilities in the
U.S. and Malaysia. Insulet products are available in 25 countries, and we're actively working to reach more customers every day.
Johor Bahru, Malaysia
Sydney
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
6
Awards
In 2025, Insulet and our products continued to receive recognition from
industry leaders.
250
Best-Managed
Companies of 2025 by the Wall Street
Journal
2025 Most Trusted Companies in America by Forbes
World's Greenest Companies 2025 and America's Most Responsible Companies
Prix Galien UK Award for Best Medical Technology (for Omnipod 5) by
Healthcare Awards: Best in Social Media/Influencers by PRWeek
2025 Medtech Big 100
2025 by Newsweek
the Galien Foundation
Hatch Awards: Elements of
by Medical Design and Outsourcing
Great Place to Work® Certification for Australia, Canada, France, Germany,
Product Design 2025 Award (for Omnipod 5 iOS App)
by Red Dot
Advertising - Music and Life Sciences - Video Long Form by The Ad Club New England
Excellence 1000 Index
Mexico, the Netherlands, the
United Arab Emirates, and
2025 by Newsweek and Best Practice Institute (BPI)
America's Greatest
the United Kingdom
Pro Patria Award
(for Insulet's support of
Silver ADCES Partnership and Impact Award
by the Association of Diabetes Care and Education
Specialists
Silver SABRE Award in Medical Technology
(for "The Pod Drop" song) by SABRE Awards North America
Companies 2025 by Newsweek
National Guard and Military Reserve employees)
Department of Defense, employer support of the guard and reserve
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
7
consecutive year of 20% or higher revenue growth
in constant currency4
10th
Delivered
Extending Our Leadership and Growth
DRIVEN BY INGENUITY
Expanded U.S. Omnipod 5 iPhone® App compatibility with Dexcom® G7
Announced FDA clearance for Omnipod 5 algorithm enhancements that offer greater customization and
tighter glucose management
Expanded Omnipod 5 sensor compatibility with Abbott's FreeStyle Libre® 2
Plus and Dexcom G7 sensors, providing a choice of sensors
in most markets
PROVEN BY SCIENCE
Shared data from Insulet's RADIANT trial that links Omnipod 5 use to significant improvements in A1C (hemoglobin A1C) levels compared with those using
multiple daily injections7
Saw continued interest in the SECURE-T2D trial results, which showed significant glycemic and quality-of-life improvements for people with type 2 diabetes with the use of Omnipod 5 compared with prior methods of
insulin delivery8
Omnipod 5
recognized as the
most requested5 and prescribed6
AID system in the U.S.
BORN OF EMPATHY
Continued global expansion with the launch of Omnipod 5
in nine new markets in 2025
In collaboration with Marvel, we launched an original comic featuring Dyasonic, a hero who
lives with type 1 diabetes
Expanded our U.S. Pod recycling program to encompass all 50 states, reflecting our commitment to
advancing the circular economy
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
8
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 9
Our Products
Simplifying life for people with diabetes and their caregivers
IN THIS SECTION
Omnipod 5 11
Customer Centricity 17
INSULET | SUSTAINABILITY REPORT 2025
Our Products
Insulet's products are designed to make life simpler for people with diabetes and their caretakers.
Omnipod offers continuous insulin delivery, providing all the benefits of insulin pump therapy while eliminating the need for multiple daily injections or traditional pumps with tubing. With its wearable design, each disposable Pod provides up to three days of continuous insulin delivery.
Our products incorporate more than 20 years of manufacturing expertise in serving our customers and ensuring continuity of supply.
Omnipod provides all the benefits of insulin pump therapy through a unique delivery system. The primary components of Pod therapy are:
POD
The tubeless, waterproof 9 Pod features automated, virtually pain-free insertion. It can be worn in multiple locations to deliver precise, personalized insulin doses for up to three days.
CONTROLLER OR PERSONAL DIABETES MANAGER (PDM)
The handheld Controller wirelessly programs the Pod with the user's personalized insulin instructions, and it monitors the operation of the Pod. The
Omnipod 5 App can also be used with iPhone
and Android compatible smartphones.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
10
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 11
Omnipod 5
The Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is our flagship product, combining the tubeless, discreet form factor of the Pod with a continuous glucose monitor to simplify diabetes management.
HIGHLIGHT STORY
Convenience That Counts: The Omnipod 5 App
Omnipod 5 provides a fully on-body wearable AID experience that has been shown to significantly improve glycemic outcomes while reducing the daily burden of living with insulin-requiring diabetes. The tubeless and waterproof9 Pod simplifies wearability, is discreet, and can remain connected for everyday activities. That simplicity and ease of use, coupled with strong results, broad access, and affordability, continue to drive its rapid adoption.
Omnipod 5 includes a proprietary AID algorithm built into the Pod. The Pod communicates via Bluetooth with a sensor/continuous glucose monitor (CGM) to obtain glucose data and predict future levels. The Pod and CGM are in continuous communication.
From this data, the algorithm determines the amount of insulin the user needs using their target glucose and automatically adjusts the dose.
Omnipod 5 helps to correct for high glucose and helps protect against low glucose day and night to improve time in range and lower A1C while keeping the incidence of hypoglycemia low.10,11,12
When a user wishes to bolus or change their Pod, they use the Omnipod 5 App, which is available on a compatible personal smartphone (U.S. market) or the Insulet-provided handheld device, known as a Controller. Data from the Omnipod 5 System is automatically uploaded to Insulet's cloud-based technology via a built-in SIM card within the Controller or through the user's mobile device.
Omnipod 5 offers integration with multiple sensors. In most of Insulet's markets, Omnipod 5 integrates with the Dexcom G6 and G7 CGMs and Abbott's FreeStyle Libre 2 Plus sensor.
60%
In the U.S., the majority (60%) use their personal phone as their primary way of controlling
Omnipod 5.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 12
We anticipate expanded integration with Abbott's FreeStyle Libre 3 Plus sensor in 2026.
In addition to Omnipod 5, we continue to offer and fully support Omnipod DASH®, which features a smartphone-like color touch screen personal diabetes manager (PDM) that is used to control the secure Bluetooth-enabled Pod. Many Podders continue to transition from Omnipod DASH to
Omnipod 5, and we provide resources and support to ensure a seamless transition.
Increasing access to Omnipod 5 remains a top priority for us. Following its 2022 U.S. launch, Omnipod 5 became available in the U.K. and Germany in 2023, and in France and the Netherlands in 2024.
In 2025, we saw a marked increase in our global reach. Omnipod 5 launched in Denmark, Finland, Italy, Norway, and Sweden in January,
Australia and Belgium in March, and Canada and Switzerland in April.
Notably, Omnipod 5 is the first AID system to hold Food and Drug Administration (FDA) clearance for both type 1 and type 2 diabetes in the U.S.
HIGHLIGHT STORY
A Palette With a Purpose: Pantone Omnipod Mango
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 13
Enhancements to the Omnipod 5 Algorithm
New
100 mg/dL
Target Glucose option expands Omnipod 5's customization
range
In December 2025, we announced FDA 510(k) clearance for significant enhancements to the Omnipod 5 algorithm. The advancements set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option for more time in range (TIR) and improvements in alert handling intended to result in more time in automated mode. These features address the two
interruptions, even during prolonged high glucose events. These advancements are designed to deliver strong clinical results with increased flexibility and greater ease of use, with fewer interruptions to daily life. We expect to launch the updated Omnipod 5 algorithm in the U.S. during the first half of 2026.
PODDER SPOTLIGHT
Milli Jefferson
PODDER SINCE 2023
most requested enhancements by Podders. The algorithm changes marked the most significant algorithm advancement to the Omnipod 5 System since its 2022 launch.
The new 100 mg/dL Target Glucose option expands Omnipod 5's customization range to six settings between 100-150 mg/dL in 10 mg/dL increments.
That allows healthcare providers to tailor insulin
delivery more precisely, supporting people seeking tighter glucose management or those striving to meet specific glucose goals. It also directly impacts
"Omnipod 5
automated insulin delivery and improves the algorithm's responsiveness. Real world evidence has shown that lowering the glucose target is associated with increased TIR with no clinically meaningful change in time below range (TBR).13
In addition, the upgraded Omnipod 5 algorithm helps users stay in Automated Mode with fewer
has been
life-changing for me."
- SPONSORED PODDER
MILLI JEFFERSON
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 14
HIGHLIGHT STORY
Landmark Studies: RADIANT and SECURE-T2D
65%
In addition to improving their HbA1c, Omnipod 5 users spent an additional 5.4 hours per day
with glucose levels in the target range compared with MDI plus CGM users, resulting in a final average time in range of 65%,
up from 39% at baseline.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 15
INSULET | SUSTAINABILITY REPORT 2025
PODDER SPOTLIGHT
Ben Nordstrom
PODDER SINCE 2023
"Omnipod is helping me be me."
- SPONSORED PODDER
BEN NORDSTROM
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 16
HIGHLIGHT STORY
Dyasonic, a Diabetes Management Hero
94%
94% of people with
type 1 diabetes want to see people with
diabetes accurately represented.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 17
Customer Centricity
As we shape the future of diabetes management, we keep customers at the center of all we do.
By practicing customer centricity, we facilitate the development of safe, high-quality products that advance a world where diabetes demands less.
We prioritize innovations that reduce customer effort, while upholding rigorous quality and safety standards from clinical trials through production.
Customer feedback is vital in helping our cross-functional product development teams create innovative solutions, and it is also critical to helping us continuously improve our products.
INSULET | SUSTAINABILITY REPORT 2025
Customer-Centered Design Customer Training
We strive to develop products that meet a variety of customer needs, lifestyles, and preferences, bringing our innovation and ingenuity to help simplify diabetes management for more people.
We designed our organizational model to strengthen our commercial capabilities, foster more innovation, and further empower cross-functional collaboration. In doing so, the model supports strong momentum, accelerates our robust pipeline, and drives our continued global expansion.
Directly engaging with customers, caregivers, and healthcare professionals enables us to better understand the improvements they need and want. We employ a variety of methods to inform our innovation pipeline, including quantitative and qualitative approaches as well as human factors studies.
When we participate in conferences with the diabetes community and healthcare professionals, we often take advantage of these opportunities to listen and learn, including conducting focus groups on diabetes technology and related services.
Our access strategy focuses on ensuring positive health outcomes for people with diabetes across communities. Our pivotal SECURE-T2D study on the efficacy of the Omnipod 5 AID System for type 2
diabetes included racial and ethnic populations historically underrepresented in clinical research - but that comprise a representative population
of those diagnosed with diabetes in the U.S. By ensuring inclusivity in clinical trials, as well as in our outreach and education programs, we can improve treatment efficacy and outcomes for more people. We continue to work to ensure inclusive representation among our clinical trial participants worldwide to build better products and outcomes for the people who need them.
Omnipod products are designed to be easy to use, which lightens the training needs of healthcare professionals, customers, and caregivers. We recognize diabetes management can be complex, and the first few weeks of using Omnipod 5 are often decisive for new customers.
With that in mind, our comprehensive, user-friendly Omnipod training materials ease the transition to Pod therapy, promote successful health outcomes, and support user retention.
Our onboarding and training content is streamlined, meeting customers where they are. Varying by geography, they typically include training videos, online user guides, and Pod University™ - a one-stop source with interactive guides about living with diabetes and diabetes management.
Through virtual training, users can onboard in a comfortable environment with family members present. These online training offerings are often vital for people in rural areas and others with limited access to healthcare providers. In addition, our Field Clinician team provides face-to-face training for new customers, caregivers, and healthcare providers.
As we reach more people with type 2 diabetes in the U.S., we are enhancing and updating our educational content to reflect the needs and
preferences of this population. As we describe in the Partnering With Associations and Advocacy Groups section of this report, we are also exploring avenues such as training pharmacists on Omnipod 5. This reflects the fact that many people with type 2 diabetes are seen by primary care physicians who may have limited experience with AID devices, and pharmacies are the primary way U.S. customers access their devices.
Our training content is accessible via computers and mobile devices. In addition to materials
in English and Spanish, we support in-person training in a wide range of languages through our translation services. We continuously seek opportunities to improve materials, enhance readability and understanding, and promote
successful health outcomes. To learn more, please visit the Omnipod website, https://www.omnipod.com.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION
OUR PRODUCTS
SUSTAINABILITY APPROACH
RESILIENT OPERATIONS
SUSTAINABLE PRODUCT INNOVATION
PEOPLE AND COMMUNITIES
GOVERNANCE
APPENDIX
18
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 19
Customer Satisfaction
Our Consumer Marketing and User Experience teams collect customer feedback through ongoing customer surveys, call-center interactions, and extensive research. In addition to our Podders, we value and welcome feedback from all members
of the diabetes community, including healthcare providers, payors, advocacy organizations, and retailers, as we develop products that produce positive health outcomes and enhance our customers' journeys with Omnipod.
When customers engage with Insulet, we seek to meet them where they are and empower them to interact with us on their terms. That includes live agent chat in the U.S., the U.K., and Australia, as well as 24/7 phone support. Our dedicated, highly trained Product Support team members answer questions about our products and
assist with troubleshooting. Through Omnipod
24/7
Our customers engage with us through live agent chat in the U.S., the U.K., and Australia, as well as 24/7 phone support.
us to move immediately into troubleshooting and problem-solving - true to our promise of making diabetes a smaller part of people's lives. In our International Product Support operations, we reduced call handling times by 30 seconds via cloud data integration and other AI initiatives.
Looking ahead, we are exploring AI-based interpretation tools that can broaden the range
HIGHLIGHT STORY
Reengaging People With Omnipod 5
artificial intelligence (AI) support, our team has immediate access to relevant content, eliminating the need for manual searches and empowering the team to provide improved guidance. In 2025, we incorporated cloud data into our customer relationship management systems. When a Podder calls in with an issue, our representatives can
now immediately identify the Pod lot number and determine how long it has been worn. This allows
of languages for training and product support. We are also investigating additional ways to support healthcare professionals who are new to AID devices, such as faster order processing and enhanced order tracking.
We continue to innovate to make it even easier for Podders, healthcare professionals, and caregivers to contact us, and to ensure the customer care experience meets and exceeds their expectations.
Our new retention
initiative helps ensure Podders' success
with Omnipod.
INSULET | SUSTAINABILITY REPORT 2025
INTRODUCTION OUR PRODUCTS SUSTAINABILITY APPROACH RESILIENT OPERATIONS SUSTAINABLE PRODUCT INNOVATION PEOPLE AND COMMUNITIES GOVERNANCE APPENDIX 20
Innovation and Intellectual Property Data and Technology
To maintain our competitive advantage, we must develop and safeguard the proprietary elements of our technologies. We protect our intellectual property through a combination of patents, trademarks, trade secrets, copyrights, nondisclosure agreements, and other protective measures.
At the end of 2025, we had over 1,000 patents and more than 700 patent applications
pending. These patents and pending
At Insulet, all data collection occurs within the context of strict data privacy processes and safeguards.
We understand that the data we collect represents private health information, and it is our responsibility to safeguard it and ensure that our platform follows stringent privacy protocols. We approach that responsibility with the utmost seriousness.
When we do use customer data, it is pseudonymized. We apply privacy-enhancing techniques to protect the
>1,000
At the end of 2025, we had over 1,000 patents.
applications cover hardware, software, and other areas of innovation.
Our Research and Development teams collaborate to evaluate innovative solutions, incorporate advanced algorithms, enhance digital integration,
and reduce resource use as they design new products and portfolio enhancements.
identity of our customers while complying with the applicable laws and regulations of the markets in which we operate. Since every Omnipod 5 user is connected to the cloud, upon customer consent we have access to
real-world data that shows us how our products perform under real-world conditions. The resulting insights help us enhance our products, with uses including algorithm design, evaluating new features, or tailoring our user support tools. As we learn from usage patterns, we can continually strengthen the customer care experience - from diagnosis through every stage of a Podder's journey - while also making it easier to interact with our support team when issues arise. To learn more, see the Customer Satisfaction section of this report.
INSULET | SUSTAINABILITY REPORT 2025
Disclaimer
Insulet Corporation published this content on May 04, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 04, 2026 at 16:24 UTC.